Application of a 6,8-dihydroxypurine compound in the preparation of anti-hepatitis B virus drugs

A technology of hydroxypurine and hepatitis B virus, which is applied in 6 fields, can solve the problems of many side effects, poor tolerance, and inability to de novo anti-virus, etc., and achieve the effect of inhibiting core protein assembly, wide application prospects, and good anti-viral effect

Inactive Publication Date: 2020-05-22
SUN YAT SEN UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, interferon-α and pegylated interferon-α-2α have many disadvantages, such as poor tolerance, frequent subcutaneous administration (interferon-α), many side effects, high cost, etc.; Except for NOV-205, which is a small molecule non-nucleoside antiviral drug listed in Russia, the other six antiviral drugs are nucleosides / nucleotides that act on the reverse transcriptase (RT) of hepatitis B virus Analogs, which suffer from resistance and side effects (eg, nephrotoxicity and myopathy)
Moreover, none of the current antiviral drugs can de novo antiviral against HBV itself, and cannot completely remove hepatitis B virus

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of a 6,8-dihydroxypurine compound in the preparation of anti-hepatitis B virus drugs
  • Application of a 6,8-dihydroxypurine compound in the preparation of anti-hepatitis B virus drugs
  • Application of a 6,8-dihydroxypurine compound in the preparation of anti-hepatitis B virus drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Study on the Effect of 6,8-Dihydroxypurine on Inhibiting the Reciprocal Binding of HBV c Antigen

[0028] Experimental method: Take well-grown human adrenal cell line 239t cells and inoculate them in a 96-well transparent flat-bottomed plate, with 5×104 cells per well. The medium used is complete medium: high-glucose DMEM, 10% fetal bovine serum and 1% double antibody, the culture condition is 5% carbon dioxide, 37°C; C and pcDNA3.1-HBVcAg-VFP-N two plasmids. For transfection, liposome-encapsulated transfection was used, lipo2000 was used as the reagent, and 20 μl of transfection solution was used. After 4 hours of transfection, compound A to be screened was added, 2 μl per well, with a final concentration of 50 μM. After culturing for 48 hours, the expression of green fluorescent protein VFP was detected. If there is a decrease in the expression of green fluorescent protein VFP, the compound may become an antiviral drug candidate. Experimental results such as figu...

Embodiment 2

[0030] 6,8-Dihydroxypurine inhibits viral replication of wild-type HBV

[0031] Experimental method: Take the well-grown cell line HepG2.2.15 that can produce wild-type HBV virus, the amount of cells is 2×104 / well, add compound A after 24 hours of laying on a 96-well plate, and compound 2 μl per hole (final concentration 250 μM, 50 μM , 10 μM, 2 μM, 0.4 μM, 0.08 μM, 0.016 μM, 0 μM); use 2% Triton X-100 to treat the collected supernatant, harvest the cultured cell supernatant for 8 days, and then detect the HBV content in the cell culture supernatant DNA content. Experimental results such as figure 2 shown. It can be seen from the experimental results that 6,8-dihydroxypurine has a good effect of inhibiting the replication of wild-type HBV virus, and its IC50 is 1.891 μM.

Embodiment 3

[0033] Cytotoxicity of 6,8-dihydroxypurine in 293t cells

[0034] Experimental method: use DMEM culture medium containing 10% fetal calf serum to prepare 293t into a single cell suspension, inoculate 1000 cells per well into a 96-well plate with a volume of 200ul per well; 2 μl, the final concentration is 50 μM, 5 μM, 0.5 μM, 0.05 μM, 0.005 μM, 0.0005 μM, 0 μM; after 48 hours of culture, add 20 μl of MTS solution to each well, and continue to incubate in the incubator for 2 to 4 hours; The light absorption value of each well was measured on an enzyme-linked immunosorbent monitor, and the cytotoxicity of the compound to 293t cells was observed. Experimental results such as image 3 shown. It can be seen from the experimental results that 6,8-dihydroxypurine has low toxicity, and it shows no cytotoxicity in 293t cells.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an application of a 6,8-xanthine compound in preparing anti-HBV (Hepatitis B Virus) drugs. The 6,8-xanthine compound according to the invention is used for preparing the anti-HBV drugs, has a function of inhibiting HBV core protein assembly, is capable of fundamentally inhibiting HBV, has no toxic side effect to cells and has a wide application prospect at the aspect of HBVtreatment.

Description

technical field [0001] The invention belongs to the application technical field of ethanol compounds, and relates to the application of a 6,8-dihydroxypurine compound in the preparation of anti-hepatitis B virus drugs. Background technique [0002] Hepatitis B virus (HBV) infection is an important public health problem worldwide. After acute hepatitis B virus infection, about 8% still develop into chronic hepatitis B infection, and persistent HBV infection will lead to liver cirrhosis and even liver cancer. my country is a big country with hepatitis B, and there are nearly 130 million hepatitis B virus carriers, accounting for about 9% of the total population. Although the new hepatitis B infection rate has been effectively controlled with the widespread popularization of hepatitis B vaccine, the population base of hepatitis B carriers is large, and the prevention and treatment of hepatitis B has become the top priority of public health problems in my country. Hepatitis B ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/52A61P31/20
CPCA61K31/52A61P31/20
Inventor 潘婷张辉
Owner SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap